Perspectives

The Importance of Engaging Patients and Patient Advocates Throughout the Medicine Development Cycle

On November 4, 2022, Lumanity collaborated with MAPS and the Patient Focused Medicines Development (PFMD) collaborative to host a webinar drawing attention to the importance of effective patient engagement with those with lived experience: patients and patient advocates.

View Jan 18, 2023

Featured

Serving the Underserved: Helping Marginalized Communities Develop Sustainable Programs for Life

View Dec 9, 2022

Is the whole greater than the sum of its parts?

View Oct 18, 2022

The Launch Rollercoaster: Riding the highs and lows

Whitepaper Dec 13, 2022

Opportunities for Enhanced Communication between Manufacturers and US Payers (Part 1)

View Jan 9, 2023

Medical Affairs Unscripted | Our Medical Affairs Journey Continues

Podcasts Jan 30, 2023

Opportunities for Enhanced Communication between Manufacturers and US Payers (Part 2)

View Jan 20, 2023

Do You Really Know How Your Market Works?

Whitepaper Jan 18, 2023

Opportunities for Enhanced Communication between Manufacturers and US Payers (Part 1)

View Jan 9, 2023

Comparing Outcomes Pre- and Post-Cancer Drugs Fund

In this paper we look at the 18 appraisals that had entered and exited the CDF between June 2016 and April 2022 to provide insights on what manufacturers can expect from the CDF and to understand whether the CDF is operating optimally to resolve genuine uncertainty in submissions.

Whitepaper Oct 19, 2022